| |
|
|
X4 Pharmaceuticals Inc (NASDAQ: XFOR) |
|
|
|
|
X4 Pharmaceuticals Inc's EBITDA Margin by quarter
Trends, Rankings, Statistics
|
Select the Comparisons :
|
|
Select the Ratio:
|
|
| XFOR EBITDA Margin |
(Mar 31 2025)
Q1 |
(Dec 31 2024)
Q4 |
(Sep 30 2024)
Q3 |
(Jun 30 2024)
Q2 |
(Mar 31 2024)
Q1 |
| Y / Y Revenue Change |
- |
- |
- |
- |
- |
| Seq. Revenue Change |
1908.86 % |
156.07 % |
-0.53 % |
- |
- |
| Revenue In Millions |
$28.81 |
$1.43 |
$0.56 |
$0.56 |
$0.00 |
| EBITDA Margin |
2.75 % |
-2289.12 % |
-6071.43 % |
- |
- |
| EBITDA Margin Total
Ranking |
# 2485 |
# |
# |
# 7 |
# |
| EBITDA In Millions |
$0.79 |
$-32.83 |
$-34.00 |
$93.22 |
$-49.81 |
| Y / Y EBITDA Change |
- |
- |
- |
- |
- |
| Seq. EBITDA Change |
- |
- |
- |
- |
- |
| Commenting First Quarter 2025 EBITDA Margin |
X4 Pharmaceuticals Inc achieved EBITDA of $1 millions compare to Operating Loss of $-32.83 millions recorded in the previous quarter. Revenue increased by 1908.86 % Company accomplished below the average EBITDA Margin with 2.75 %.
Observing first quarter 2025 results within Biotechnology & Pharmaceuticals industry 22 other companies have achieved higher EBITDA Margin. While EBITDA Margin overall ranking has deteriorated relative to the three months before, from to 2485.
Learn about Operating Margin
|
| XFOR's EBITDA Margin first quarter 2025 Company Ranking |
| Within: |
No. |
| Biotechnology & Pharmaceuticals Industry |
# 23 |
| Healthcare Sector |
# 213 |
| Overall |
# 2485 |
| EBITDA Margin Statistics |
| High |
Average |
Low |
| 16557.9 % |
8280.33 % |
2.75 % |
| (Jun 30 2024) |
|
(Mar 31 2025) |
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
